These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7379441)

  • 1. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
    Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
    Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massive propranolol metabolite retention during maintenance hemodialysis.
    Stone WJ; Walle T
    Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
    Ring JA; Ghabrial H; Ching MS; Shulkes A; Smallwood RA; Morgan DJ
    Drug Metab Dispos; 1995 Feb; 23(2):190-6. PubMed ID: 7736910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-dealkylation of propranolol in rat, dog, and man. Chemical and stereochemical aspects.
    Nelson WL; Bartels MJ
    Drug Metab Dispos; 1984; 12(3):345-52. PubMed ID: 6145562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of diltiazem versus cimetidine on propranolol metabolism.
    Tateishi T; Ohashi K; Fujimura A; Ebihara A
    J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of aging on the oxidative and conjugative metabolism of propranolol.
    Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
    Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
    Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
    Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation.
    Ghabrial H; Nand R; Stead CK; Smallwood RA; Morgan DJ
    J Pharm Sci; 1994 Jul; 83(7):931-6. PubMed ID: 7965671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.
    Bianchetti G; Graziani G; Brancaccio D; Morganti A; Leonetti G; Manfrin M; Sega R; Gomeni R; Ponticelli C; Morselli PL
    Clin Pharmacokinet; 1976; 1(5):373-84. PubMed ID: 1017154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)lactic acid as a metabolite of propranolol in the rat, in man, and in the rat liver 9000 g supernatant fraction.
    Talaat RE; Nelson WL
    Drug Metab Dispos; 1986; 14(2):202-7. PubMed ID: 2870895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions.
    Lo MW; Pond SM; Effeney DJ; Silber BM; Riegelman S; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):401-12. PubMed ID: 6527232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
    Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
    Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cutaneous biotransformation of propranolol.
    Cormier M; Ledger PW; Marty JP; Amkraut A
    J Invest Dermatol; 1991 Sep; 97(3):447-53. PubMed ID: 1875045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.